Tranylcypromine
(1R,2S)-(+)-tranylcypromine (left), (1S,2R)-(−)-tranylcypromine (right) | |
| Clinical data | |
|---|---|
| Trade names | Parnate, many generics |
| Other names | trans-2-Phenylcyclopropylamine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682088 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Drug class | Monoamine oxidase inhibitor; antidepressant |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Metabolism | Liver |
| Elimination half-life | 2.5 hours |
| Excretion | Urine, Feces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.005.312 |
| Chemical and physical data | |
| Formula | C9H11N |
| Molar mass | 133.194 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| | |
Tranylcypromine, sold under the brand name Parnate among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI). It is used primarily as an antidepressant in the treatment of major depressive disorder, including treatment-resistant depression. Along with phenelzine and isocarboxazid, tranylcypromine is one of the classic irreversible, non-selective MAOIs used in modern psychiatric practice.
Tranylcypromine is also known as trans-2-phenylcyclopropyl-1-amine and is formed pro forma from the cyclization of amphetamine's isopropylamine side chain. As a result, it is classified structurally as a substituted phenethylamine and amphetamine, or more specifically as a phenylcyclopropylamine.